News
Why Sarepta Therapeutics Stock Gained 10.7% in July
Sarepta Therapeutics (NASDAQ: SRPT), a biotech developing novel treatments for rare disorders, saw its shares rise by a healthy 10.7% last month, according to S&P Global Market Intelligence. The
Illumina vs. Intuitive Surgical: Which Company Reported Better Earnings?
Illumina (NASDAQ: ILMN) and Intuitive Surgical (NASDAQ: ISRG) recently reported second-quarter earnings that were better than industry watchers' forecasts. These two game-changing healthcare companies
AstraZeneca plc: Buy the Dip?
AstraZeneca plc (NYSE: AZN) stock tumbled after the company announced the failure of an important clinical trial recently. Although the shares have recovered somewhat, the stock is still off by about
Why Vertex Pharmaceuticals Skyrocketed 17.8% in July
After reporting results from mid-stage trials showing its multi-drug combination therapies improved lung function in cystic fibrosis patients, Vertex Pharmaceuticals (NASDAQ: VRTX) shares surged 17.8%
Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important
It's been a pretty good year for Juno Therapeutics (NASDAQ: JUNO) so far. The clinical-stage biotech's share price is up more than 50% year-to-date. Its financial position in the first quarter looked
Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter
Momenta Pharmaceuticals (NASDAQ: MNTA) continued to tread water in the second quarter, waiting for approval by the U.S. Food and Drug Administration of its copycat of the three-times weekly version of
3 Reasons to Still Buy Exelixis Stock After Its Strong Q2 Performance
Any way you look at, Exelixis (NASDAQ: EXEL) just reported an impressive second-quarter performance. The biotech posted its second quarter of profitability, with earnings topping Wall Street
Here's Why Teva Pharmaceutical Industries Ltd (ADR) Is Sinking Like a Stone
In response to reporting rough second-quarter results, shares of Teva Pharmaceutical Industries (NYSE: TEVA), a leading provider of generic drugs, dropped 24% as of 1:15 p.m. EDT on Thursday.Here's a
Teva Pharmaceutical Industries Ltd. Slashes Full-Year Outlook After Disappointing Second Quarter
Buying the Actavis Generics business from Allergan (NYSE: AGN) made the difference for Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) when it reported first-quarter results in May. That deal boosted
Masimo Corporation Raises Full-Year Guidance After Second-Quarter Earnings Soar
Investors thoroughly enjoyed learning how Masimo Corporation (NASDAQ: MASI) performed in the first quarter back in May. The maker of non-invasive monitoring technologies reported impressive revenue
Pacific Biosciences of California Struggles in the Second Quarter With Lower Sales
Pacific Biosciences of California (NASDAQ: PACB) didn't fare so well the last time it provided a quarterly update. After the genetic-sequencing company reported its first-quarter results in late
ResMed Tops Expectations but Falls Anyway
Medical-device maker ResMed (NYSE: RMD) reported its fiscal fourth-quarter results after the market closed on Tuesday, Aug. 1. The continuous positive airway pressure (CPAP) pioneer reported modest
3 Reasons the Best Is Yet to Come for Celgene
Celgene Corp.'s (NASDAQ: CELG) second-quarter revenue and sales came in nearly 50% higher than they were two short years ago, yet the company doesn't appear to be anywhere near peaking. A flurry of
10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings
IDEXX Laboratories, Inc.'s Investors Look the Gift Horse in the Mouth
IDEXX Laboratories (NASDAQ: IDXX) reported solid revenue growth with operating income and earnings growing even faster allowing the animal diagnostic company to raise 2017 guidance.But investors
Illumina Soars After Crushing Expectations for Q2
In response an upbeat second-quarter report and bullish guidance, shares of Illumina (NASDAQ: ILMN), a leading provider of genetic testing equipment, rose Wednesday morning. The stock was up by 13.3%
A Large-Scale Acquisition Is Unlikely for Pfizer Until This Happens
Pharma titan Pfizer (NYSE: PFE) announced second-quarter earnings on Tuesday, but the drugmaker's performance was clearly a secondary issue for analysts and investors alike. Despite beating consensus
3 Companies Building the World of Tomorrow
It's always intriguing to think about what new technologies the future will bring. But what you might not realize is that many of the building blocks of tomorrow are already in place. And lucky for
Illumina Inc. Blows Past Guidance in Second Quarter With Strong NovaSeq Demand
Illumina Inc. (NASDAQ: ILMN) started out 2017 on a positive note by beating its first-quarter revenue guidance and coming in at the upper end of its earnings guidance. However, there were a few
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
Here's Why the Best Is Yet to Come for Exact Sciences
Millions of Americans forego getting tested for colon cancer; however, a new colon cancer test from Exact Sciences (NASDAQ: EXAS) is changing that, and as a result, patients are catching their cancer
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
Why Clovis Oncology Tumbled 13.5% Today
After disclosing that it's entered into a pact with Bristol-Myers Squibb (NYSE: BMY) on its cancer-fighting drug Rubraca, shares in Clovis Oncology (NASDAQ: CLVS) lost 13.5% of their value Monday.
Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today
The stock market saw a lot of indecision on Monday, as major benchmarks moved in different directions. The Nasdaq Composite was weaker than most of its peers, but the Dow Jones Industrials jumped to